January 2025

Contents

Editorial

• i-Base appeal: Q&A services and the website in 2025

Special reports

• Looking back through 2024 and forward to 2025…

• ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir

Antiretrovirals

• Transient impact of lenacapavir against MDR HIV-2 without other active ART

• Lenacapavir submitted to the US FDA with an indication for HIV PrEP

mpox (monkeypox)

• Detailed results from Palm007 study: no clinical impact of tecovirimat against mpox clade 1

• Tecovirimat news continues: Japan approval includes mpox indication

Future meetings

• Future meetings and webinars 2025